Axogen Inc

Axogen, Inc. (NASDAQ: AXGN) is a medical device company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company serves surgeons treating peripheral nerve injuries across four key markets: Extremities (traumatic and chronic nerve injuries), Oral Maxillofacial & Head and Neck (OMF/H&N), Breast (nerve reconstruction during breast cancer surgery), and an emerging Prostate market (cavernous nerve repair during robotic prostatectomy). Axogen's product portfolio includes Avance (the only FDA-approved biologic nerve scaffold for treating peripheral nerve discontinuities), Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and the recently acquired NerveTape (a coaptation aid eliminating micro-suturing). The company estimates a $5.6 billion U.S. total addressable market across its four focus areas and has established access in more than 2,700 hospitals and outpatient centers, supported by a direct sales force of over 160 representatives. Avance has achieved approximately 96% commercial payer coverage of U.S. covered lives, and over 275,000 patients have been treated with Axogen's products. Updated Oct 28, 2026